BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results

  Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA

  November 14, 2019

   · 

  11 min read
• Business

  BrainsWay to Report Third Quarter 2019 Financial Results on November 25, 2019

  BrainsWay Ltd., a global leader in the advanced non-invasive treatment of brain disorders, announced that it will report its third quarter 2019 financial results before the opening of the U.S. financial markets on Monday, November 25, 2019.

  November 14, 2019

   · 

  4 min read
• Business

  Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress

  Eton Pharmaceuticals, Inc reported financial results for the third quarter ended September 30, 2019 and provided an update on business progress.

  November 14, 2019

   · 

  8 min read
• Drug Development

  Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

  Reflects company values and commitment to patients living with hypoparathyroidism

  November 14, 2019

   · 

  8 min read
• Business

  Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results“Emerges with the financial strength, development focus and cost structure to achieve long-term viability and growth”

  Plus Therapeutics, Inc. announced financial and business results for the third quarter of 2019.

  November 14, 2019

   · 

  7 min read
• Business

  Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

  Viela Bio reported financial results and provided program highlights for the third quarter ended September 30, 2019.

  November 14, 2019

   · 

  10 min read
• Business

  Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments

  Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021

  November 14, 2019

   · 

  7 min read
• Business

  CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business UpdateConference Call Scheduled for Today at 4:30 p.m. Eastern Time

  CorMedix Inc. announced financial results for the third quarter and nine months ended September 30, 2019 and provided an update on recent business developments.

  November 14, 2019

   · 

  9 min read
• Business

  Zyla Life Sciences Reports Third Quarter 2019 Financial Results

  Positive net cash flow of $6.5 million for the quarter ended September 30, 2019

  November 14, 2019

   · 

  10 min read
• Business

  Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results

  In July 2019, Titan announced a specialty product distribution agreement for Probuphine® (buprenorphine) implants with CVS Caremark, a subsidiary of CVS Health.

  November 14, 2019

   · 

  15 min read